Biotech Values

[DewDiligence]

What I am asking is how does inequitable conduct directly effect the outcome of a potential launch of Copaxone.

Inequitable conduct is one of the four arguments by which NVS/MNTA hope to get around Teva’s Copaxone patents—see #msg-56147443.

The main Copaxone issue for MNTA investors, however, is the timing of FDA approval. If the FDA approves NVS/MNTA’s ANDA before the Copaxone patent litigation has run its course, I expect that Teva will quickly settle, rendering our speculation about the various legal arguments superfluous.